Top 50 Biotechnology Angel Investors in United Kingdom (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
31 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Nadav Rosenberg
Angel
|
6 | United Kingdom, France, Israel | Seed, Pre-Seed, Series A | Software, Biotechnology, Artificial Intelligence | $850k–$21M |
|
Darrin Disley
Angel
|
4 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | $458k–$3.7M |
|
Charlie Songhurst
Angel
|
4 | United Kingdom, United States, Germany | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $542k–$8.5M |
|
Peder Nielsen
Angel
|
4 | United Kingdom | Seed, Convertible Note | Biotechnology | |
|
Jude Gomila
Angel
|
4 | United States, United Kingdom, India | Seed, Pre-Seed, Angel | Software, Information Technology, Biotechnology | $70k–$5M |
|
Ian Hogarth
Angel
|
3 | United Kingdom, United States, Germany | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $698k–$43M |
|
Paul Wicks
Angel
|
3 | United Kingdom, United States, Japan | Seed, Pre-Seed, Series A | Software, Wellness, E-Commerce | $539k–$11M |
|
Jeff Dean
Angel
|
3 | United States, United Kingdom, Japan | Seed, Series A, Pre-Seed | Artificial Intelligence, Information Technology, Software | $450k–$60M |
|
Edward Lando
Angel
|
3 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, FinTech | $125k–$37M |
|
Nadav Ben-Chanoch
Angel
|
3 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Information Technology, Artificial Intelligence | $120k–$30M |
|
Milad Alucozai
Angel
|
3 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $110k–$60M |
|
Hugh Grant
Angel
|
3 | United Kingdom | Seed, Convertible Note | Biotechnology | |
|
DrPano Kroko Churchill
Angel
|
3 | United Kingdom | Angel, Series A | Health Care, Therapeutics, Biotechnology | $150k–$458k |
|
Stefano Bernardi
Angel
|
3 | Italy, United Kingdom, France | Seed, Pre-Seed | Software, Blockchain, Biotechnology | $100k–$45M |
|
Ariel Poler
Angel
|
2 | United States, Spain, Mexico | Seed, Series A, Angel | Software, Social Media, Internet | $455k–$7.9M |
|
Amar Shah
Angel
|
2 | United Kingdom, Poland, Germany | Pre-Seed, Seed, Angel | Artificial Intelligence, Software, Health Care | $642k–$15M |
|
Jon Oringer
Angel
|
2 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Information Technology, FinTech | $100k–$31M |
|
Gilad Engel
Angel
|
2 | France, Israel, United Kingdom | Seed, Pre-Seed | Hardware, Analytics, Biotechnology | $1.2M–$1.9M |
|
Aidan Gomez
Angel
|
2 | United States, United Kingdom, Canada | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, Information Technology | $1.8M–$12M |
|
Simon Galbraith
Angel
|
2 | Croatia, United Kingdom | Seed, Pre-Seed, Venture - Series Unknown | Software, Health Care, Life Science | |
|
Vishal Rao
Angel
|
2 | United States, India, Canada | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $500k–$25M |
|
Pratima Aiyagari
Angel
|
2 | United Kingdom, France, Germany | Seed, Pre-Seed, Series A | SaaS, Analytics, Cyber Security | $1M–$12M |
|
Ed Parkinson
Angel
|
2 | United Kingdom | Seed | Health Care, Life Science, Biotechnology | $1.9M–$3M |
|
Abdulaziz Alrashed
Angel
|
2 | United Kingdom | Seed, Pre-Seed | Analytics, Biotechnology, Information Technology | |
|
Mati Staniszewski
Angel
|
2 | United States, United Kingdom, Poland | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, SaaS | $2M–$75M |
|
Mark Evans
Angel
|
2 | United Kingdom, United States, The Netherlands | Series A, Seed | Retail, Fashion, Software | $1.4M–$24M |
|
Michelle Tempest
Angel
|
2 | United Kingdom | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Cannabis | |
|
Jim Mellon
Angel
|
2 | United States, United Kingdom, Germany | Series A, Seed | Biotechnology, Food and Beverage, Health Care | |
|
Nicholas Edwards
Angel
|
2 | United Kingdom | Seed, Venture - Series Unknown | Medical, Health Care, Life Science | |
|
Patrick Pichette
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $943k–$95M |
|
Tim Davis
Angel
|
2 | United States, United Kingdom, Germany | Series A, Series B, Seed | Health Care, Biotechnology, Medical | |
|
Ersin Pamuksüzer
Angel
|
2 | Turkey, Germany | Seed, Series A | Education, Life Science, Virtual Reality | $300k–$500k |
|
Inaki Berenguer
Angel
|
2 | Spain, United States, United Kingdom | Seed, Angel, Pre-Seed | FinTech, Financial Services, E-Commerce | $233k–$9M |
|
Chris Mairs
Angel
|
2 | United Kingdom, United States | Seed, Pre-Seed, Angel | Software, FinTech, Financial Services | $334k–$5M |
|
Damien Lane
Angel
|
2 | United Kingdom, United States, Ireland | Seed, Pre-Seed, Series A | SaaS, Software, Health Care | $459k–$16M |
|
Serge Chiaramonte
Angel
|
2 | United Kingdom, United States, France | Seed, Pre-Seed | FinTech, Financial Services, Software | $637k–$37M |
|
Paul Forster
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series A, Pre-Seed | Software, FinTech, Financial Services | $1.1M–$18M |
|
Matt Clifford
Angel
|
2 | United Kingdom, United States, India | Seed, Pre-Seed, Venture - Series Unknown | Software, Artificial Intelligence, FinTech | $55k–$34M |
|
Jan Hruska
Angel
|
2 | United Kingdom | Seed, Venture - Series Unknown | Medical, Health Care, Life Science | |
|
Robert Kopple
Angel
|
2 | United States, United Kingdom | Convertible Note, Venture - Series Unknown | FinTech, Finance, Life Science | $3.3M–$4.8M |
|
Bradley Horowitz
Angel
|
2 | United States, United Kingdom, Germany | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $150k–$120M |
|
Tim Dempsey
Angel
|
2 | United Kingdom | Seed, Series A | Software, SaaS, Financial Services | $962k–$13M |
|
Nicolas Berggruen
Angel
|
2 | United States, United Kingdom, Brazil | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $850k–$26M |
|
Taz Patel
Angel
|
1 | United States, United Kingdom | Seed, Series A | SaaS, Information Technology, Mobile | |
|
Mark McCamish
Angel
|
1 | United Kingdom | Seed | Medical, Biopharma, Biotechnology | |
|
Jon Moulton
Angel
|
1 | United Kingdom, Cyprus, Luxembourg | Seed, Series A | Financial Services, FinTech, Banking | |
|
Sharaf Yamani
Angel
|
1 | India, United Kingdom | Seed | Biotechnology, Software, Life Science | |
|
Sunil Shah
Angel
|
1 | United Kingdom | Seed, Series A, Post-IPO Equity | Health Care, Biotechnology, Pharmaceutical | |
|
Oliver Sexton
Angel
|
1 | United Kingdom | Seed, Pre-Seed | Biotechnology, Health Care, AgTech | |
| Access all 232 angel investors in United Kingdom Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 62
- Round size: Seed $537k–$25M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
- Nuclera — Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Israel
Investor stats
- Total investments: 15
- Round size: Seed $850k–$3.1M; Pre-Seed $2M–$2M; Series A $18M–$21M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Teora — Crude oil derived products have infiltrated every industry – synthetic colors, flavors, fragrances in food, dyes in textiles, fertilizers and packaging material that harm humans and the planet. TeOra’s mission is to replace synthetics with naturals that are manufactured in a sustainable and predictable manner. A microorganism is the best factory,optimized over billions of years of evolution and TeOra designs it to produce desired products. Using microfluidics and AI, TeOra offers 100 times faster and cheaper design of smart micro-organisms in weeks to months instead of years.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Lindus — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
Darrin Disley is based out of Cambridge, Cambridgeshire, and is the Executive Chairman and Director of Cardiogeni. Darrin previously worked at Mogrify as Chief Executive Officer, Director, and Investor. Darrin Disley attended the University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 5
- Round size: Seed $458k–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- bit.bio — Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 214
- Round size: Seed $1.1M–$8.5M; Pre-Seed $542k–$5.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skrap — Skrap is an on-demand mobile marketplace for skip hire and other waste collection services.
- Uncovr — Surgical video is the biggest dark data in medicine. We turn it into operative reports, billing codes, and clinical intelligence automatically
- Structured AI — Construction AI QA/QC software that automatically reviews drawing packages and catches errors, code issues, and coordination clashes before they reach the field.
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 64
- Round size: Seed $1.4M–$5M; Angel $70k–$1.3M; Pre-Seed $660k–$2.9M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Vaire — Conventional chips waste all their energy as heat. Vaire's groundbreaking technology will recover and recycle most of its energy, delivering low energy, high performance compute for the AI era.
- Clara — Clara is an AI-powered primary care doctor.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
Ian Hogarth is based out of London, England, and is the Chairman of Phasecraft. Ian previously worked at Songkick as a Chairman. Ian Hogarth attended the University of Cambridge.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 60
- Round size: Seed $1.5M–$7.9M; Pre-Seed $698k–$7.5M; Series A $11M–$43M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
- Cordless — Bridging the gap between voice and text
- Fabric — Fabric is an AI-powered workspace and file manager for people and groups.Fabric is a self-organizing multiplayer workspace.
Paul Wicks, Ph.D., is a strategic advisor and independent consultant who helps digital health and life science companies turn data into evidence, evidence into influence, and influence into impact. He has supported over 40 organizations including AstraZeneca, Ada Health, Biogen, Click Therapeutics, and Woebot.Previously, Paul spent 13 years as VPof R&D at PatientsLikeMe, building one of the world’s largest patient communities and pioneering decentralized trials, digital biomarkers, and real-world evidence. He has authored over 200 peer-reviewed papers and served on editorial boards of journals including the BMJ, Digital Biomarkers, and BMC Medicine.A neuropsychologist by training, Paul completed his Ph.D. at King’s College London and a postdoc on the psychology of Parkinson’s disease. His work has been featured by BBC, CNN, and The New York Times. He was named MIT Technology Review’s “Humanitarian of the Year” in 2011 and is a TED Fellow and FLIER alumnus of the Academy of Medical Sciences. He is an honorary Professor at the University of Birmingham.
Show more...Investment focus
- Industry: Software, Wellness, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 17
- Round size: Seed $3M–$6.6M; Pre-Seed $539k–$1M; Series A $6.7M–$11M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Stelia — Stelia builds distributed AI platforms that scale globally. Research-driven intelligent systems for healthcare, education, and enterprise operations worldwide
- Epiminds — Epiminds develops multi-agent AI systems to run marketing end-to-end.
- Scooch — All-in-one subscription to eliminate hassle from your pet healthcare. From online assessment, health tracking and AI assistant to 24/7 vet support and vet-formulated treatments.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Japan
Investor stats
- Total investments: 104
- Round size: Seed $2.5M–$35M; Pre-Seed $450k–$2.3M; Series A $10M–$60M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Moonlake AI — Vibe code games and worlds into existence.
- Belfort — Enabling Fully Homomorphic Encryption through Hardware Acceleration
- Periodic Labs — From bits to atoms.
Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 478
- Round size: Seed $975k–$7M; Pre-Seed $125k–$3.4M; Series A $5.5M–$37M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Humera — Humera - AI CAPTCHA That Knows You're Human
- Allonic — Allonic is a robotics hardware company pioneering 3D Tissue Braiding, a new manufacturing platform for producing integrated, compliant, bio-inspired robotic bodies through a single, fully automated production process. By eliminating assembly-heavy designs and supply-chain complexity, Allonic enables significantly faster iteration, lower costs, andsafer, more dexterous robots to be built. Originally founded from Hungary and operating internationally with a US HQ and a growing team of 15, Allonic is building the hardware foundation for the next generation of intelligent machines.
- Heywa Labs — Heywa Labs develops Generative UX (GenUX), an AI-driven interface layer that creates dynamic, adaptive user experiences beyond static text or links. Their flagship app, Heywa, delivers visual, tappable "stories" of cards for tasks like cooking, travel, fitness, and DIY, reconfiguring in real-time based on user interactions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Nadav Ben-Chanoch
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 226
- Round size: Seed $500k–$6M; Pre-Seed $120k–$2.5M; Series A $4M–$30M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- micro1 — We help companies hire and manage the best software engineers easily.
- TRIVER — Triver develops online and digital tools to assist and support various financial services. It is based in London, England.
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 55
- Round size: Seed $1M–$7M; Pre-Seed $110k–$5M; Series A $13M–$60M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Replit — Replit is a simple yet powerful online IDE, Editor, Compiler, Interpreter, and REPL. Code, compile, run, and host in 50+ programming languages.
- Revalia Bio — Revalia Bio develops curative drugs for chronic organ-centered disease.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Hugh Grant is the Chief Executive Officer at H.B.Grant and Associates.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Industry: Health Care, Therapeutics, Biotechnology
- Stage:Angel, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Round size: Angel $150k–$458k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Blockchain, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: Italy, United Kingdom, France
Investor stats
- Total investments: 17
- Round size: Seed $100k–$45M; Pre-Seed $874k–$2.2M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Freatic — Building the monetization layer for your alpha
- Niulinx — Niulinx specializes in providing autonomous driving technology solutions based on artificial intelligence, connectivity, and data analytics.
- Automated Architecture — A global ecosystem of automated micro-factories, to deliver sustainable, affordable and beautiful architecture to millions of people.
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more...Investment focus
- Industry: Software, Social Media, Internet
- Stage:Seed, Series A, Angel
- Geography: United States, Spain, Mexico
Investor stats
- Total investments: 45
- Round size: Seed $455k–$7M; Angel $1M–$1.7M; Series A $3M–$7.9M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Goin — Goin is a Barcelona-based fintech platform founded in 2017 that provides a unified money optimization ecosystem combining automated savings, investments, digital assets, and rewards. The app enables users to aggregate multiple bank accounts via PSD2, centralizing financial data and automating decisions through its AI engine, gaIA. Goin integratesfinancial automation, portfolio tools, and cash-back incentives in a single interface used primarily by young European consumers. The company operates in a regulated environment, is registered with the Bank of Spain as a crypto service provider, and has expanded across Southern Europe. In 2025, Goin launched KernelPay, its B2B Banking-as-a-Service (BaaS) infrastructure for payments, accounts, and wallet management.
- Reloadly — Send gift cards, airtime & payouts globally with one API. Scalable, instant, developer-friendly platform for rewards and incentives.
- Openlytics — Openlytics is a Visual Data Platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape the direction ofthe product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
Amar Shah is based out of London and is the Founder & Partner of Dhyan VC. Amar previously worked at Firstminute Capital as an Entrepreneur In Residence. Amar Shah attended the University of Cambridge.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Pre-Seed, Seed, Angel
- Geography: United Kingdom, Poland, Germany
Investor stats
- Total investments: 10
- Round size: Seed $4.8M–$15M; Pre-Seed $642k–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Emm — Emm is developing the next generation of consumer health tools to manage your health on your terms. We want to empower everyone to change the quality of their life by inherently understanding their health though technology and specialist knowledge.
- Tolemy Bio — The AI-native virtual cell platform for therapeutic development and manufacture.
- ReSpo.Vision — Enhance your sports analytics and visualise the game using AI & Computer Vision-powered Sports Tracking and Event Data.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Industry: Software, Information Technology, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 133
- Round size: Seed $1.1M–$5.5M; Pre-Seed $100k–$3.4M; Series A $4M–$31M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- SLUSHY — SLUSHY is a secure mobile web based platform for content creators to find, grow, & monetize their audiences. A creator first, tech-driven tool, designed with key discoverability features and audience insights. In a market where existing solutions (OnlyFans, Patreon) fall short of their creators' demands, SLUSHY provides an alternativesolution for professional content creators that prioritizes their monetization, support and management needs. SLUSHY incorporates a powerful legal framework, with robust compliance tools including simplified consent, ID verification, and content moderation. The new home of unrestricted content, SLUSHY is here.
- Unsloth AI — Unsloth is an open-source, no-code web UI for training, running and exporting open models in one unified local interface.
- OneImaging — OneImaging makes life-saving diagnostics affordable, accessible, and personal. We connect employers, health plans, and members to a trusted national network of imaging centers, delivering faster answers with transparent pricing and premium care across MRIs, CT scans, ultrasounds, mammograms, X-rays and more. We serve organizations looking to control medical spend and individuals who need reliable results without delays. Every scan booked through OneImaging is proof that healthcare can be simpler, cheaper, and kinder.
Gilad Engel
Show more...Investment focus
- Industry: Hardware, Analytics, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: France, Israel, United Kingdom
Investor stats
- Total investments: 4
- Round size: Seed $1.2M–$1.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Fourier Optics — Fourier optics creates meta-surface based optical systems for Augmented Reality glasses
Aidan Gomez is based out of Toronto, Ontario and is the co-founder & CEO at Cohere. Aidan Gomez attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 17
- Round size: Seed $2.8M–$12M; Pre-Seed $1.8M–$3.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- DatologyAI — DatologyAI optimize training efficiency, maximize performance and reduce compute costs with expert curation.
- Extropic AI — The next era of computing isn't dead. It's alive. More coming soon.
- Helical — The full power of DNA & (m)RNA Bio Foundation Models in one open-core platform. Accelerate Drug Discovery with AI.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Simon is the joint founder and CEO of Redgate Software. Over the past 15 years, Simon has been part of Redgate’s growth from a 2 person firm operating out of a spare room to today’s 300 person outfit with hundreds of thousands of users. Although Simon’s responsibilities are primarily strategic, his background is technical with qualificationsincluding a PhD in physics from Cambridge University and former employment with Shell and ThornEMI.
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Croatia, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- BoobyBiome — BoobyBiome harnesses breast milk microbiome science to develop products to improve infant health
- Syskit — Syskit Point keeps your Microsoft 365 environment under control - secured, cost-optimized, and AI confident.
Advisory CTO and Angel Investor
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, India, Canada
Investor stats
- Total investments: 84
- Round size: Seed $500k–$8.8M; Pre-Seed $500k–$2.1M; Series A $3.8M–$25M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Aquaria — Aquaria provides solutions to secure access to clean water. The organization adapts its approaches based on the needs of these communities. It addresses water-related challenges through various methods.
- Delphi — Delphi turns your expertise into an always-on presence, so you can grow your reach, serve your audience, and lead with clarity, without burning out.
- Cambridge Terahertz — Cambridge Terahertz, a leader in terahertz (THz) imaging technology, offers an AI-powered Concealed Weapons Detection (CWD) solution to enhance workplace security. Our patent-pending system can see through clothing, luggage, plastic, paper, ceramics, and cardboard to detect concealed threats, including firearms, knives, and explosives.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Industry: SaaS, Analytics, Cyber Security
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Germany
Investor stats
- Total investments: 11
- Round size: Seed $1.2M–$8.3M; Pre-Seed $1M–$1.2M; Series A $7M–$12M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Mindflow — Mindflow is a No-Code & Agentic Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks and to deploy AI Agents at scale.
- ESPROFILER — ESPROFILER uniquely combines security spend, commercials, and capabilities with threats helping security leaders maximise their investments.
Ed Parkinson
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $1.9M–$3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
Abdulaziz Alrashed.
Show more...Investment focus
- Industry: Analytics, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Mati Staniszewski is the Co-Founder of ElevenLabs.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Poland
Investor stats
- Total investments: 22
- Round size: Seed $4.5M–$11M; Pre-Seed $2M–$20M; Series A $16M–$75M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- imagi — Programming has never been this much fun! Learn to create with code, share your designs with friends on the imagiLabs app and customize your imagiCharm - a fun, easy-to-use, colorful, and educational toy for girls. Imagine it. Code it. Wear it.
- Dwelly — Dwelly acquires and partners with independent UK lettings agencies, helping owners exit smoothly, profitably and on their terms. Get a free agency valuation.
- Arrakis Security — Secure the enterprise agents where they're deployed. Total visibility, governance, and remediation for the autonomous workforce.
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more...Investment focus
- Industry: Retail, Fashion, Software
- Stage:Series A, Seed
- Geography: United Kingdom, United States, The Netherlands
Investor stats
- Total investments: 36
- Round size: Seed $1.4M–$8M; Series A $3.2M–$24M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- ONI — Where are you in your super-resolution journey? ONI is here to support you along your super-resolution journey Answer a few simple questions to discover key resources that can help you make the most of single-molecule imaging technology across a wide range of applications Products Gallery FAQs Subscribe to our mailing list
- Ufonia — Dora is a clinical AI agent that calls and supports your cataract patients, empowering your ophthalmology practice to scale without compromise on care.
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Michelle Tempest
Show more...Investment focus
- Industry: Health Care, Biotechnology, Cannabis
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Daye — Daye is setting a new standard in period care and gynae health. We offer period products, vaginal microbiome screenings, and a period pain clinic.
- Sanome — Sanome are combining different types of biomarkers to develop engaging, useful and accurate diagnostic products (IVDs) that enable early detection and prevention of disease. The IVD innovation engine, will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people.
- Medwise.ai — Medwise.ai is the Google for doctors.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Health Care
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 29
- Lead/follow: no public data
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Patrick Pichette is based out of London, England, and is the Partner of Inovia Capital and also Board Member of Cohere. Patrick Pichette previously worked at Twitter as a Board of Directors. Patrick Pichette attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 27
- Round size: Seed $943k–$10M; Series A $10M–$95M; Series B $15M–$95M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
- Kaedim — AI-powered 3D asset creation service delivering fast, production-ready 3D assets. Scale 3D pipelines without hiring, accelerate 3D game art production, and reduce 3D asset costs by up to 90%.
- Clove — Building the financial institution of the future, to make money make sense.
Timothy T Davis, MD is Board Certified in Physical Medicine and Rehabilitation (Physiatry) and Pain Medicine. The founder of Source Healthcare, Source Surgery Center, Alpha Diagnostics and he is an expert in spine and musculoskeletal disorders as well as interventional pain management to treat neck, back and sports injuries. Dr. Davis hasperformed extensive clinical research using biological therapies such as stem cells and other biologics for spine and joint injuries. He has consulted and invested in SaaS, medical device, biologics, cannabis, and psychedelics sectors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 10
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bryn Pharma — Bryn Pharma is a pharmaceutical company that offers nasal-based epinephrine for anaphylaxis. Its bi-dose intranasal device is an alternative to epinephrine auto-injectors and is needle-free. It is easy to use and portable enabling patients to treat allergic reactions or anaphylactic reactions.
- Beckley Psytech — Our mission is to help people suffering from neurological and psychiatric conditions by developing our pipeline of psychedelic compounds.
- MycoMedica Life Sciences, PBC — Psychedelic Medicines
Ersin Pamuksüzer
Show more...Investment focus
- Industry: Education, Life Science, Virtual Reality
- Stage:Seed, Series A
- Geography: Turkey, Germany
Investor stats
- Total investments: 5
- Round size: Seed $300k–$500k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aposto — All-in-one media service currently based in Istanbul, Turkey.
- VRLab Academy — VRLab Academy | Virtual Experiments
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- Industry: FinTech, Financial Services, E-Commerce
- Stage:Seed, Angel, Pre-Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 27
- Round size: Seed $500k–$9M; Angel $233k–$1M; Pre-Seed $1.2M–$2M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Goin — Goin is a Barcelona-based fintech platform founded in 2017 that provides a unified money optimization ecosystem combining automated savings, investments, digital assets, and rewards. The app enables users to aggregate multiple bank accounts via PSD2, centralizing financial data and automating decisions through its AI engine, gaIA. Goin integratesfinancial automation, portfolio tools, and cash-back incentives in a single interface used primarily by young European consumers. The company operates in a regulated environment, is registered with the Bank of Spain as a crypto service provider, and has expanded across Southern Europe. In 2025, Goin launched KernelPay, its B2B Banking-as-a-Service (BaaS) infrastructure for payments, accounts, and wallet management.
- Permisso — Bankflip is a mobile application that collects and processes income, tax, employment, and relevant data in real-time.
- Momento — Momento is an insurtech company with the objective of revolutionizing the insurance industry in Latin America, starting with car insurance. We want to make insurance easy and accessible for the underserved population in LATAM.
Chris Mairs - Venture Partner @ Entrepreneurs First
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Pre-Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 26
- Round size: Seed $655k–$5M; Angel $334k–$707k; Pre-Seed $900k–$2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
- Briefcase — AI agents that capture invoices, code transactions, handle VAT, reconcile banks, and build working papers in real time. Fully integrated with Xero and QuickBooks. Two-week free trial.
- Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Damien Lane has spent the last 20 years investing in private companies, both in Private Equity where he was a partner with Electra Partners, then at Octopus Ventures where he was a senior member of the investment team. Having made a number of angel investments, Damien co-founded Episode 1 with Simon and Adrian in 2012. While at Episode 1,Damien has led investments in Carwow, Scurri, Touch Surgery, Attest and Zipcube and loves working with early stage teams of entrepreneurs; helping them develop their early stage startup into a fast growth enterprises capable of raising more funding from later stage investors. When he is not trying to help businesses to implement an optimal approach to growth, Damien can mostly be found running around Hampstead Heath or the Coastal paths of Great Britain. Having trained obsessively to run a 2:52 Marathon in 2015, he is now trying to dip below 2:50, in the spirit of continuous improvement. Damien has an MBA from Cambridge University and a Masters degree in PE from Oxford University.
Show more...Investment focus
- Industry: SaaS, Software, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 38
- Round size: Seed $459k–$3.1M; Pre-Seed $660k–$1M; Series A $3.2M–$16M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Calira — Calira (formerly Clustermarket). Give researchers an easy way to book equipment, improve equipment utilisation, and get structured lab usage data.
- Realla — Search the entire commercial property market for offices, serviced office space, retail, industrial for sale and to rent
- Jump — Launched in late 2018 after 2 years of R&D supported by competitive grant funding from the UK & NL Government, Jump is a people analytics platform that gives everyone a chance to succeed. By understanding what makes people unique and linking this to business outcomes, Jump gives more personalised job recommendations to professionals, inturn attracting much better job applications to businesses. Win:win for both!Jump is backed by outstanding investors whose successes include Revolut, CarWow, GoodLord, Magic Pony and many others. Jump collaborates with Imperial College and other top UK Universities in the development of the data science and algorithms behind Jump.Looking for new career options or just a change of scenery? Sign up and receive personalised job matches - absolutely and always for free - at https://app.jump.work/jobsLooking to transform your talent attraction using people analytics? Drop me a note and we can chat!
Serge Chiaramonte
Show more...Investment focus
- Industry: FinTech, Financial Services, Software
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 63
- Round size: Seed $1.2M–$5.3M; Pre-Seed $637k–$37M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
- StackOne — Accelerate your SaaS growth with our unified API solution for HRIS, ATS, and CRM. Say "yes" to customers, build advanced integrations quickly, and experienced the best data privacy controls in the market.
- Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.
Paul Forster is an early-stage investor in the tech sector. He previously worked at Indeed as a Senior Advisor. Paul attended INSEAD, where he earned an MBA.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 81
- Round size: Seed $1.1M–$7.2M; Pre-Seed $1.1M–$3.5M; Series A $3.9M–$18M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Oraion — Your single source of truth for enterprise data
- Capsa AI — Providing next-generation investors with a competitive edge.
- Habito — We're the Treating Customers Fairly Champion of 2023 as voted for in the British Bank Awards. We're here to make mortgages easier - no paperwork, no stress and no fees.
Matt co-founded EF after being a consultant at McKinsey & Co. Prior to EF Matt spent his time studying at MIT fuelled by an obsession with R, Python and unusual datasets. EF is the best place for Europe’s top technical individuals to meet and build world-changing startups in London.They select purely on the basis of technical talent, so youcan apply before you have a team or an idea. The intensive 6-month programme is designed to give you the best possible support in the first 200 days of your startup’s life.They have created over 40 startups now worth over $300 million. The startups are funded by some prestigious investors including Balderton Capital, Index Ventures, Octopus Investments and Y Combinator.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 41
- Round size: Seed $764k–$7M; Pre-Seed $55k–$4.2M; Venture - Series Unknown $2.4M–$34M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Stackfix — Stackfix operates as a software comparison platform.
- Rivan Industries — Rivan Industries designs and builds modular, vertically integrated, synthetic fuel plants.
- Asymmetric Security — Asymmetric Security is an AI-native cybersecurity startup specializing in digital forensics and incident response. It combines elite forensic experts with proprietary AI to accelerate investigations, especially Business Email Compromise (BEC) attacks, at less than half the cost of competitors while shrinking timelines from days to hours.
Jan Hruska
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Robert C. Kopple is based out of Vancouver, Ontario, and is the Partner of Kopple, Klinger & Elbaz. Robert previously worked at Gelum Resources as a Board of Directors. Robert C. Kopple attended New York University.
Show more...Investment focus
- Industry: FinTech, Finance, Life Science
- Stage:Convertible Note, Venture - Series Unknown
- Geography: United States, United Kingdom
Investor stats
- Total investments: 3
- Round size: Venture - Series Unknown $3.3M–$4.8M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
- ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 132
- Round size: Seed $150k–$18M; Series A $7.2M–$36M; Series B $19M–$120M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Key AI — Unlock new networking and career opportunities with Key, the leading AI-powered professional networking platform. Build and manage communities, host and join exclusive events, and create meaningful connections to supercharge your growth all in one place.
- Catena Labs — Catena is a product studio where we transform complex computing advancements into accessible, practical tools for users and developers. Leveraging AI and web3 technology our aim is to turn innovative ideas into real-world applications that are easy to use.
- Odyssey — Odyssey is an AI lab pioneering general world models: causal, multimodal systems that learn to understand and simulate the world.
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more...Investment focus
- Industry: Software, SaaS, Financial Services
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 18
- Round size: Seed $962k–$2.7M; Series A $6.4M–$13M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
- AeroCloud — Reinvent airport management with cloud-based software that enhances efficiency, unifies operations, and helps airports deliver a seamless, people-first experience.
Nicolas Berggruen is the Founder and Chairman of the Berggruen Institute. He attended New York University.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 34
- Round size: Seed $850k–$4.5M; Series A $7M–$25M; Series B $25M–$26M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Helm.ai — Explore Helm.ai's AI software for high-end ADAS through Level 4 autonomous vehicles. Helm.ai offers a full suite of full-stack AI software, foundation models, and generative AI development and validation tools for production-bound projects.
- The Data Foundation — Story is AI-native infrastructure for the intellectual property economy.
- iLoF — iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development
Taz Patel is a serial entrepreneur with multiple exits over the past decade who continues to support the startup ecosystem via mentorship, advisory and investing. Most recently, Taz co-founded Captiv8, an Influencer marketplace and SaaS platform funded by Social Capital, Liquid 2, Visionnaire, Jason Calacanis, Cyan Banister and strategic Angels.Before this, Taz was the Chief Revenue Officer of Republic Project, a startup funded by Google Ventures and later acquired by DG Sizmek in 2013. Before that, Taz led monetization efforts at Showyou App funded by True Ventures that was acquired by Vevo in 2015. His knowledge in social marketing, mobile/video advertising, and SaaS/Marketplace businesses is a personal passion that stems from early sales leadership roles at Interclick and BlueLithium, both of which were acquired by Yahoo! for $270 Million in 2011 and $300 Million in 2007. A Chicago native, Taz studied at the University of California, Berkeley and currently lives with his wife, son and dog in San Francisco.
Show more...Investment focus
- Industry: SaaS, Information Technology, Mobile
- Stage:Seed, Series A
- Geography: United States, United Kingdom
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- CloudAdmin.io — CloudAdmin is a cost-optimization platform that helps executives save money in hidden cloud instance buying options.
- Ampleforth — Ampleforth is the name of a character in George Orwell's 1984 who is responsible for translating poetry into Newspeak, a language designed to limit freedom of thought. When tasked to replace the word “God” in a Kipling poem, Ampleforth refuses, not out of righteousness, or subversiveness, but rather, a simple love for language and respect forthe truth. To Ampleforth, no other word makes sense in context and therefore no other word should replace it.
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University
Show more...Investment focus
- Industry: Medical, Biopharma, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.
Show more...Investment focus
- Industry: Financial Services, FinTech, Banking
- Stage:Seed, Series A
- Geography: United Kingdom, Cyprus, Luxembourg
Investor stats
- Total investments: 18
- Lead/follow: no public data
Portfolio highlights
- Pockit — Open a prepaid account in 3 minutes online or in-app, get your contactless prepaid card in 2 working days with no credit check.
- Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
- Hellas Direct — Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and artificial intelligence. The Cyprus-based company is backed by a roster of leading investors, including Portag3, IFC (a member of the World Bank), Endeavor Catalyst, former Goldman Sachs economist Lord O’Neill and private equity veteran JonMoulton. Modelling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence.
Sharaf Yamani - Managing Director @ Windlesham Advisors
Show more...Investment focus
- Industry: Biotechnology, Software, Life Science
- Stage:Seed
- Geography: India, United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Sunil Shah is the CEO and Co-Founder of o2h group. He previously worked at India-UK Cancer Research Initiative (CRUK-DBT) as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Stage:Seed, Series A, Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 8
- Lead/follow: no public data
Portfolio highlights
- Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
- PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
- Five Alarm Bio — Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.
Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.
Show more...Investment focus
- Industry: Biotechnology, Health Care, AgTech
- Stage:Seed, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 10
- Lead/follow: no public data
Portfolio highlights
- twig bio — twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Biotechnology Angel investor funding in United Kingdom at a glance
Stats across 195 deals from 232 investors.
Access all 232 angel investors in United Kingdom Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Angel Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 232 angel investors investing in United Kingdom Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!